Trials / Completed
CompletedNCT00517920
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
Detailed description
An Open-label, Phase 2 study of efficacy and tolerability of ABT-869 in advanced hepatocellular carcinoma (HCC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-869 | 0.25 mg/kg QD |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2011-06-01
- Completion
- 2012-06-01
- First posted
- 2007-08-17
- Last updated
- 2013-01-04
Locations
6 sites across 4 countries: United States, Canada, Singapore, Taiwan
Source: ClinicalTrials.gov record NCT00517920. Inclusion in this directory is not an endorsement.